Drug Hunter

AUGUST 21, 2023

Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. Prodrugs Remain in “Proof-of-Concept” Stages Prodrug strategies for CNS deliver have also been applied with varying success , with the most famous example being L-Dopa for Parkinson’s disease. Figure 18.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206

New Drug Approvals

SEPTEMBER 6, 2024

US10071079, Example 15 Ref WO2018005586 [link] The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to TLR modulation, such as inflammatory and autoimmune diseases, and methods of inhibiting the activity of TLRs in a mammal.

RNA 62

RNA Clinical Trials DNA Disease 62

Drug Target Review

NOVEMBER 17, 2023

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Dr Huimin Cao Senior Research Fellow, Cartherics Dr Madeline Cao received her MD in 2010 and practiced at Institute of Hematology & Blood Diseases Hospital in Tianjin, China.

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

Drug Target Review

SEPTEMBER 19, 2023

The chips can be modelled with primary cells, IPS derived stem cells or patient derived cells and potentiates to unlock molecular mechanisms that drive the disease pathophysiology, holding a greater promise. The first successful chip adaptation to a lung model was first described in 2010 by Donald Ingber, a bioengineer at Wyss institute.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

The Pharma Data

MARCH 5, 2021

Food and Drug Administration (FDA) approved Actemra ® /RoActemra ® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. 1-3 SSc affects about 2.5

FDA 52

FDA Disease FDA Approval Therapies 52

NIH Director's Blog: Drug Development

FEBRUARY 27, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH A major part of NIH’s mission is to support basic research that generates fundamental knowledge about the nature and behavior of living systems. As outlined in the paper, the researchers first identified all new molecular entities (NMEs) approved by the FDA from 2010 to 2016.

Research 52

Research Science FDA Pharmaceutical Companies 52

Drug Target Review

SEPTEMBER 26, 2023

Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. 2010 Aug;31(4):331–50. Using stem cell-derived neurons in drug screening for neurological diseases. Johnstone AFM, Gross GW, Weiss DG, Schroeder OHU, Gramowski A, Shafer TJ.

Drugs 112

Drugs FDA Disease Animal Testing 112

The Pharma Data

JANUARY 31, 2021

At DeveloGen, Dr Dohrmann led the company to become an internationally recognised leader in metabolic diseases. DeveloGen was acquired by Evotec in 2010. Since 2010, Dr Dohrmann has been serving Evotec as Chief Scientific Officer and Member of the Management Board.

Science 52

Science Government Medical Schools International 52

Broad Institute

JUNE 8, 2010

Connectivity Map The Connectivity Map is a collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules and simple pattern-matching algorithms that together enable the discovery of decisive functional connections between drugs, genes, and diseases.

Small Molecule 40

Small Molecule Disease Drugs 40

The Pharma Data

OCTOBER 23, 2020

More than 185,000 kids took the test from 2010 to 2017. The disparities can have a profound effect on kids’ long-term development and lead to higher rates diabetes, heart disease, drug use, mental health disorders and dementia, the researchers said.

Research 52

Research Disease Drugs 52

Eye on FDA

JUNE 14, 2023

The latest letter was issued for a website that promoted a treatment for hypercortisolemia in patients with Cushings Disease. It was the second letter for this company, the first having been issued in August, 2020 for a TV advertisement. Of those without boxed warnings (9 in number), only 2 had Warning Letters.

FDA 82

FDA Production Doctors Treatment 82

Drug Target Review

JUNE 19, 2024

There are many opportunities to address conditions of the eye, such as retinitis pigmentosa, dry age-related macular degeneration or any of the hundreds of inherited retinal diseases. MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast’s merger with Savara, Inc. SVRA) in April 2017.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. NEW YORK and LONDON, Jan.

Science 52

Science Clinical Development Disease Production 52

Drug Target Review

FEBRUARY 28, 2024

Prior to that, Mr Ho was at New Leaf Venture Partners, a leading healthcare venture capital firm, where he launched and managed the public investments and cross-over portfolio, and served as its Public Investment Director from 2010 to 2014. Human γδ TCR repertoires in health and disease. References Fichtner A, Ravens S, Prinz I.

Therapies 105

Therapies Engineering Molecular Biology Science 105

NIH Director's Blog: Drug Development

MARCH 11, 2014

But this approach doesn’t just provide predictions of risk; it may also provide a path to developing new ways of treating and preventing this serious, chronic disease that affects about 26 million Americans. Over time, this leads to heart disease, stroke, blindness, nerve damage, kidney damage, and amputations. J Clin Invest.

DNA 52

DNA Drugs Disease Research Laboratories 52

The Pharma Data

MARCH 16, 2021

Head of Department CNS Diseases Research at Boehringer Ingelheim. “By While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinson’s disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders.

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

JANUARY 24, 2021

Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board. His research focuses on the role of the microbiome in immune defense and disease resistance. “We

Research 40

Research Bioinformatics Laboratories International 40

National Institute on Drug Abuse: Nora's Blog

MARCH 6, 2025

Reducing drug use has clear public health benefits, including reducing overdoses, reducing infectious disease transmission, and reducing automobile accidents and emergency department visits, not to mention potentially reducing adverse health effects such as cancer and other diseases associated with tobacco or alcohol. doi: 10.1111/j.1530-0277.2010.01290.x.

Treatment 69

Treatment Trials Clinical Trials Drugs 69

The Pharma Data

DECEMBER 20, 2020

Interventional treatment for mitral regurgitation is considered to be one of the most challenging areas in the field of structural heart disease, yet also represents huge market potential. ” HighLife was founded in 2010 by Georg Börtlein, who previously co-founded CoreValve Inc., of the McGill University Health Centre.

Licensing 40

Licensing Licensing Production Treatment 40

The Pharma Data

OCTOBER 25, 2020

If human trials confirm these results, we see hope for the first time that PAH can be turned into a manageable chronical disease,” said Dr. Shuqian Jing , founder and CEO of Gmax. About Gmax Biopharm LLC: Gmax is a clinical stage company established in 2010 and headquartered in Hangzhou, China.

Trials 40

Trials Clinical Trials Drugs Compliance 40

The Pharma Data

JANUARY 11, 2021

The WEB Aneurysm Embolization System has been CE marked since 2010 and has been used in more than 12,000 cases and multiple clinical studies throughout the world. Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. .

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

The Pharma Data

MARCH 17, 2022

AstraZeneca today launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex diseases. Rapid progress in disease understanding, as well as scientific and technological advances are genuinely changing our expectations of what is possible.

Science 40

Science Clinical Trials Disease Research 40

Drug Target Review

SEPTEMBER 20, 2023

Rob joined Cresset as CEO in 2010 and now also serves as Chairman of Cresset. Training AI/ML tools to predict results of otherwise complex and time-consuming calculations is gaining traction in pharmaceutical R&D. Rob is a Fellow of the Royal Society of Chemistry.

Drugs 105

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals 105

The Pharma Data

NOVEMBER 11, 2021

MMH provides sustainable and holistic results to communities worldwide since 2010. Centers for Disease Control and Prevention. Atlanta, GA Centers for Disease Control and Prevention,U.S.Dept. Learn more atwww.makingmorehealth.com. National Diabetes Statistics Report, 2020. of Health and Human Services; 2020.

International 40

International Disease 40

Common Sense for Drug Policy Blog

DECEMBER 20, 2023

DCRs further seek to reduce overdose-related morbidity and mortality, and prevent the spread of infectious diseases by offering access to sterile equipment, safer use advice and emergency interventions. 2010; Potier et al., 2014; Schäffer et al., 2014; EMCDDA, 2018).

Drugs 40

Drugs Disease Marketing 40

Drug Target Review

FEBRUARY 26, 2024

Alani currently serves as the Herbert Mescon Endowed Professor and Chair of Dermatology at Boston University Chobanian & Avedisan School of Medicine and the Dermatologist-in-Chief at Boston Medical Center, a position she has held since January, 2010.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

The Pharma Data

NOVEMBER 19, 2020

Prior to joining Bain in 2010, Retterath was a partner at Monitor Group and head of the New York office. Gelbman most recently served as the founding CEO of FDNA, a digital health startup that develops advanced AI tools to help diagnose patients with rare diseases.

Laboratories 52

Laboratories Research Laboratories Science Organic Chemistry 52

Broad Institute

AUGUST 2, 2023

The Sabatini Lab focuses on the development and regulation of synapses in the brain and the relationship of these processes to behavior and disease. Unemployment reached almost 25% and then declined to under 10% over the next 15 years until the less severe recession in 2009/2010. hypertension, diet quality).

Medical Schools 52

Medical Schools Disease Science International 52

The Pharma Data

DECEMBER 14, 2020

government’s Operation Warp Speed, Moderna has been working with the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID). To date, the research into the vaccines indicates it prevents symptomatic COVID-19 and appears to prevent severe disease. billion worth of vaccines.

Vaccine 52

Vaccine FDA Virus Government 52

The Pharma Data

JANUARY 18, 2021

About Biophytis Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

Regulations 40

Regulations Clinical Trials Disease Production 40

The Pharma Data

SEPTEMBER 1, 2020

We are working relentlessly to deliver solutions that help alleviate some of the healthcare burden with reliable SARS-CoV-2 testing solutions as we learn more about the disease and how it affects people around the world.”. SARS-CoV-2 Rapid Antigen Test package insert [2] European Centre for Disease Prevention and Control.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

APRIL 4, 2023

“Since receiving FDA clearance in 2010, more than 17 million CoolSculpting® treatments have been performed. Important Safety Information CoolSculpting ® and CoolSculpting ® Elite are contraindicated in patients with cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

Treatment 40

Treatment FDA Licensing Licensing 40

Drug Target Review

AUGUST 9, 2024

She has over a decade of experience in clinical and scientific research with more than 20 high impact research publications to her name, focusing on combined therapies for optimal disease control and increased quality of life. References Allen, L. Popovich, N. G., & Ansel, H. Lippincott Williams & Wilkins.

Science 59

Science Drugs Compliance Drug Development 59

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. However, 95% of the over 6,000 recognized orphan diseases still have no treatment options. countries examined between 2010 and 2017.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

Agency IQ

NOVEMBER 27, 2023

These standards were expected to be established within 30 months, or by March 27, 2010. And while it is mostly similar to what had been drafted in 2010, there are some notable changes. 1) When required. The rule comes into effect 180 days after it is made final by being published in the Federal Register.

FDA 40

FDA Science Drugs Regulations 40

The Pharma Data

NOVEMBER 15, 2020

In addition, Dr. Lee Babiss, a committed director since 2010, has announced his retirement and has stepped down from the board. This prestigious group of professionals will help lead the Company as it prepares for potential commercialization of its investigational cell therapy, MultiStem ®. About Athersys.

Clinical Trials 40

Clinical Trials Trials Production Therapies 40

Agency IQ

JUNE 7, 2024

Forty-eight Notified Bodies received designation for six codes, including software (MDA 0315), systems/procedure packs (MDS 1011), devices manufactured with metal (MDT 2001) or plastic processing (MDT 2002), devices with electronic components (MDT 2010) and devices requiring installation or refurbishing (MDT 2012).

Regulations 40

Regulations Compliance Packaging Production 40